Molecule.one, a computational chemistry outfit based in Poland, announced that it raised USD million in a seed funding round. The round was led by Atmos Ventures.
The funding round also saw the participation of investors like AME Cloud Ventures, Inventures, Cherubic Ventures, Sunfish Partners, Firlej Kastory, Luminous Ventures, and a few individuals, including Sebastian Guth.
Molecule. one claims that it will utilize this fundraised to expand its team and strengthen its footprints, it also plans to start new offices in Western Europe and the U.S.
About Molecule.one
Molecule.one is an AI-powered software for the design of organic synthesis. It was founded and established by Piotr Byrski and Paweł Włodarczyk-Pruszyński in the year 2016, having its headquarter in Mazowieckie, Poland.
It went on Disrupt SF 2019’s Startup Battlefield, where it explained and emphasised the difficulty tackled by the discovery industry of drugs, that the industries come with a lot of theoretical experiments but aren’t actually able to make the molecules.
The company strengthens machine learning and abundant knowledge about chemical reactions to create these processes. The CSO of the company explained how they work, he said –
“Synthesis planning can be characterised as a game,” he said. “In each move of this game, instead of moving a piece on a board, we break a chemical bond between a pair of atoms. The goal of the game is to break down a target molecule into molecules that can then be bought on the market and used to synthesise the target. We use algorithms similar to the ones used by DeepMind to master Go or chess to find the synthesis pathway.”
The CEO Piotr Byrski added to this, he said –
“Our system has matured, and we have extended our platform to support planning synthesis for thousands of molecules per hour,” he said. “This feature is handy when combined with AI systems for drug discovery that generate huge numbers of candidate drug molecules. All these improvements helped us gain trust in the industry and initiate collaborations with relevant parties.”
“We made part of our platform free to eligible researchers working on COVID drug discovery. This has resulted in a lasting collaboration with the LambdaZero project at MILA, which Prof. Yoshua Bengio advises. We are incredibly excited about this area in general because it enables traversing unexplored regions of the chemical space, which offers enormous promise in terms of looking for drugs that have not yet been synthesised.” – he added.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
